Separation and identification of differentially expressed nuclear matrix proteins in breast carcinoma forming

Figures & data

Figure 1. Western blot analysis of DNA topoisomerase II (A) and histone (B). Lane 1, nuclear protein of normal breast. Lane 2, nuclear matrix protein of normal breast. Lane 3, nuclear protein of breast carcinoma. Lane 4, nuclear matrix protein of breast carcinoma. β-actin as used as an internal loading control.

Figure 2. Representative 2-D gel analyses of NMPs from (A) normal breast, (B) hyperplastic mammary, (C) atypical epithelial hyperplasia and (D) breast carcinoma.

Figure 3. MALDI-TOF mass spectrum maps of Hsp27 (A), prohibitin (B) and laminA/C (C).

Table I. Differentially-expressed proteins in the different groups.

Spot. no.	Accession. no	Protein name-e	Score	MW(Da)	PI no	Peptide coverage (%)	Protein	Fold change*
								a	b	c
1	g|662841	heat shock protein 27	143	22427	7.83	11	48	+1.59	+2.08	+2.81
2	gi|33150528	osteoglycin OG	129	34243	5.33	9	18	−1.62	−1.60	−2.15
3	gi|28375587	unnamed protein product	85	43225	5.9	10	23	−1.53	−2.33	−2.04
4	gi|193787261	unnamed protein product	68	113269	5.54	8	9	−1.57	−1.78	−3.21
5	gi|55957496	LaminA/C	110	74311	6.44	13	28	+1.56	+1.65	+2.06
6	gi|38045913	Nucleoside diphosphate kinase	81	19869	5.42	6	32	+1.54	+4.02	+3.56
7	gi|4505773	Prohibitin	116	29843	5.57	9	38	+2.11	+3.56	+4.41
8	gi|34527739	unnamed protein product	66	51876	8.66	7	16	−1.85	−3.42	−3.64
9	gi|5453597	F-actin capping protein alpha-1 subunit	67	33073	5.45	5	24	−1.62	−1.61	−2.03
10	gi|127798841	ATP synthase	70	59785	9.07	9	22	+2.16	+2.12	+2.73
11	gi|28207863	unnamed protein product	75	41593	5.14	9	27	−1.54	−1.76	−2.11
12	gi|113812151	MYL6 protein	93	15923	4.60	7	42	+1.53	+1.56	+2.68

*Fold change: a: Group I/Group II; b: Group I/Group III; c: Group I/Group IV; + up-regulated;—down-regulated.

Figure 4. Western blot analysis of the Hsp27 (A), prohibitin (B) and laminA/C (C) in normal breast (Lane 1) and breast carcinoma (Lane 2). β-actin was used as an internal loading control.

Figure 5. Representative immunohistologic features of Hsp27 (A), prohibitin (B) and laminA/C (C) in normal breast and breast carcinoma (original magnification 200).

Figure 6. Correlation analysis of prohibitin expression with clinicalpathological characteristics. (A and B) The expression of prohibitin was increased from normal breast (lane 1–2), hyperplastic mammary (HM) (lane 3), to breast carcinoma (BC) lanes 4–6). However, prohibitin expression was not correlated with the differentiation status of breast carcinoma (lanes 4–6 are low-, medium-, and high-differentiated breast carcinoma, respectively).

Table II. The correlation of prohibitin with clinicalpathological features.

Groups	Cases	Band intensity ratio	p-Value (mean±SD)
Tissues
Normal breast	12	0.59±0.19
Hyperplasia of mammary gland	13	0.69±0.17
Breast carcinoma	31	1.02±0.22	0.001*
Histological type
Infiltrating special breast carcinoma	19	1.03±0.16
Infiltrating non-special breast carcinoma	12	1.01±0.31	0.850
Differentiated status
Low-differentiated	6	1.06±0.14
Medium-differentiated	12	1.02±0.17
High-differentiated	13	1.00±0.29	0.559
Clinical stages
Stage I	7	1.04±0.14
Stage II	15	1.03±0.27
Stage III	9	1.00±0.19	0.657

*Asterisk indicates a significant difference in breast carcinoma group in comparison with normal breast group.